OKYO Pharma says cash position funds completion of NEPTUNE Phase 3 urcosimod trial

• OKYO Pharma filed its annual report for the fiscal year ended March 31, 2026, citing a strengthened cash position to fund a Phase 3 program.
• February 2026 public offering raised about $22 million in gross proceeds, including overallotment, boosting liquidity.
• Cash and cash equivalents totaled about $20.6 million at March 31, 2026, with funding expected through completion of the NEPTUNE Phase 3 trial.
• NEPTUNE, an FDA-agreed global Phase 3 pivotal study of urcosimod in neuropathic corneal pain, is planned to start in H2 2026.
• Trial targets about 111 patients in the US and Europe, randomized 2:1 to 0.05% urcosimod or placebo in a single-dose regimen.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-033850), on July 20, 2026, and is solely responsible for the information contained therein.